In 2020, the global market for transcatheter heart valve management products, including transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve (TMV) repair products, totaled nearly $4.7bn, with TAVR products accounting for nearly 90% of sales. Over the forecast period covered by this report, TMV repair devices are expected to experience greater growth than the more mature TAVR market, advancing at a CAGR of approximately 20%. Drivers include a growing prevalence of valvular disease due to the aging population, positive clinical trial results for transcatheter techniques compared to open surgery, technological advancements, and expanded indications. Limiters include device cost, lack of long-term data compared to surgical intervention, and lack of trained operators and facilities in certain geographic regions. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve (TMV) repair systems for the US, five major European markets, Japan, and Rest of World markets for the years 2020–25.